A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province

• Conditions: Carcinoma;Blood

• Registration Number: NCT05130424
• Lead Sponsor: SuxiaLuo

Brief Summary

To observe and evaluate the safety and effectiveness of herombopag in the treatment of thrombocytopenia-related diseases in Henan Province

Detailed Description

This study is designed as a real-world study on the treatment of thrombocytopenia-related diseases with Herombopag, to observe and analyze the safety and efficacy of Herombopag for thrombocytopenia-related diseases in the real world.

Study Timeline

• Study Start: 2021-09-29
• Study First Submitted: 2021-10-28
• Status Verified: 2021-11
• Study First Submitted QC: 2021-11-18
• Last Update Submitted: 2021-11-18
• Study First Posted: 2021-11-23
• Last Update Posted: 2021-11-23
• Primary Completion: 2023-06
• Study Completion: 2023-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 498

Inclusion Criteria

1. Thrombocytopenia related diseases;
2. Volunteer to join this study and sign an informed consent form;
3. Clinical evaluation can benefit from Herombopag.

Exclusion Criteria

1. Those who have been confirmed to be allergic to Herombopag and/or its excipients;
2. Pregnant or breastfeeding women;
3. Except for patients with contraindications to Herombopag;
4. Doctors evaluate patients who are not suitable for inclusion.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of adverse events after the treatment of Herombopag	From the treatment of Herombopag to 28 days after the end of the medication	The investigator will observe incidence of adverse events after the treatment of Herombopag, including thrombosis, diarrhea, abnormal liver function and so on.

Secondary Outcome Measures

Name	Time	Method
Changes of the platelet counts after the treatment of Herombopag	From the treatment of Herombopag to 28 days after the end of the medication	The investigator will assess the changes of the platelet counts after the treatment of Herombopag。
Proportion of patients with platelet transfusion	From the treatment of Herombopag to 28 days after the end of the medication	The investigator will assess the proportion of patients with platelet transfusion after the treatment of Herombopag。

Trial Locations

Locations (1)

Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China